Profiling tumors in patients with parathyroid tumors
Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents
This study is testing whether analyzing tumor and blood samples from patients with parathyroid tumors can help identify important genes for better diagnosis and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 310 (estimated) |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT03039439 on ClinicalTrials.gov |
What this trial studies
This study focuses on analyzing previously collected tumor tissue and blood samples from patients with parathyroid tumors to identify differences in clinical behavior and immunohistochemical biomarkers among parathyroid carcinoma, atypical neoplasms, and adenomas. The goal is to determine potential genes that could aid in the diagnosis of these tumors. By utilizing molecular and immunohistochemical profiling, the study aims to improve diagnostic accuracy and reduce unnecessary surgical interventions. The research is conducted at the University of Texas MD Anderson Cancer Center and involves collaboration with other sites.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a known diagnosis of primary hyperparathyroidism who have previously consented to the use of their tissue or blood for research.
Not a fit: Patients without a diagnosis of primary hyperparathyroidism or those who have not consented to the use of their biological samples for research may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and tailored treatment options for patients with parathyroid tumors.
How similar studies have performed: Other studies have shown success in using molecular profiling for cancer diagnosis, indicating that this approach has potential but may also include novel aspects.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient cohort for this study consists of all patients within the prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center (MDACC) or from collaborating sites, with tissue or blood available from 1968-2015, previously consented for the use of the tissue for research purposes (via Protocols LAB 08-0034, PA11-0695 and LAB03-0320 or the appropriate external mechanism for collaborating sites). * All patients with a known diagnoses of primary hyperparathyroidism (PHPT) operated/treated in the Department of Surgical Oncology of MDACC or at a collaborating site. Patients that have provided consent for the use of the tissue or blood for research purposes will then be considered for our study (via Protocol LAB03-0320 and LAB 08-0034 or the appropriate external mechanism for collaborating sites). * All consented patients with known diagnoses of PHPT with a histopathological diagnosis of: parathyroid carcinoma, atypical parathyroid neoplasm or parathyroid adenoma. There will be no restrictions on age, gender, or ethnicity. * Selected patients obtained through outside collaboration who meet the selection criteria for tissue availability and diagnostic suitability for inclusion in the study. Exclusion Criteria: * Patients without tissue available for analysis.
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Nancy Perrier — M.D. Anderson Cancer Center
- Study coordinator: Nancy D. Perrier
- Email: nperrier@mdanderson.org
- Phone: 713-792-6940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.